Info

Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs in the areas of infectious disease, oncology and inflammation. The Company's has assembled a pipeline of clinical and preclinical product candidates in the fields of infectious diseases, oncology and inflammation. Its most advanced product candidate, cethromycin, is a second generation once-a-day oral antibiotic that recently completed pivotal phase III clinical trials in community acquired pneumonia (CAP) and in Phase III clinical development for the treatment of respiratory tract infections. The Company also has product candidates in earlier stages of development for the treatment of indications, including inflammation-related tissue damage and malignant melanoma. In August 2007, FDA designated ALS-357 an Orphan Drug for the topical treatment of metastatic melanoma.